Abstract:
|
To evaluate the class effect of VEGF-TKI as adjuvant therapy in renal cell carcinoma (RCC), a meta-analysis was conducted based on summary level data from three phase III studies: ASSURE (Haas et al., 2016), S-TRAC (Ravaud et al., 2016) and PROTECT (Motzer et al., 2017). All three studies are placebo controlled randomized phase III studies in patients with intermediate or high risk of relapse to RCC, and sorafenib, sunitinib and pazopanib were studied respectively. The primary endpoint for all three studies is disease free survival (DFS).
The VEGF-TKI effect vs placebo was estimated via hazard ratio and 95% confidence/credible intervals using both frequentist and Bayesian approaches in the meta-analysis.
|